Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration.

OBJECT: The outcome for children with recurrent malignant brain tumors is poor. The majority of patients die of progressive disease within months of relapse, and other therapeutic options are needed. The goal of this Phase I study was to evaluate the safety of in vivo suicide gene therapy in 12 children with recurrent, malignant, supratentorial brain tumors. METHODS: After optimal repeated tumor resection, multiple injections of murine vector-producing cells shedding murine replication-defective retroviral vectors coding the herpes simplex virus thymidine kinase type 1 (HSV-Tk1) gene were made into the rim of the resection cavity. Fourteen days after the vector-producing cells were injected, ganciclovir was administered for 14 days. The retroviral vector that was used only integrated and expressed HSV-Tk1 in proliferating cells, which are killed after a series of metabolic events lead to cell death. The median age of the patients was 11 years (range 2-15 years). Treated brain tumors included seven malignant gliomas, two ependyminomas, and three primitive neuroectodermal tumors. The patients were treated with one of three escalating dose concentrations of vector-producer cells. Four transient central nervous system adverse effects were considered possibly related to the vector-producing cells. In no child did permanent neurological worsening or ventricular irritation develop, and tests for replication-competent retroviruses yielded negative findings. CONCLUSIONS: This Phase I study demonstrates that in vivo gene therapy in which a replication-defective retroviral vector in murine vector-producing cells is delivered by brain injections can be performed with satisfactory safety in a select group of children with localized supratentorial brain tumors.

Glucocorticoids inhibit stress-induced phosphorylation of CREB in corticotropin-releasing hormone neurons of the hypothalamic paraventricular nucleus.

The corticotropin-releasing hormone (CRH) gene contains a perfect palindromic motif in its promoter region that allows binding of the cyclic adenosine monophosphate response element binding protein, CREB. Since previous studies suggest that the CRH gene can be activated by cyclic adenosine monophosphate, we determined whether stress and feedback inhibition by glucocorticoids in CRH-producing neurons in the hypothalamic paraventricular nucleus could be mediated by changes in the phosphorylation of CREB. Antisera to CREB and phospho-CREB Ser133 (PCREB), the active phosphorylated form of CREB, were used for immunohistochemical studies on rat brain. In nonstressed animals CREB immunostaining was confined to the nucleus of cells ubiquitously throughout the hypothalamus, while PCREB immunostaining was discretely localized in magnocellular neurons and only a few cells in the medial parvocellular subdivision of the paraventricular nucleus. Ether and handling stress markedly increased the number of PCREB-labeled neurons in the parvocellular subdivision. Double immunolabeling with CRH antiserum revealed that the majority of hypophysiotropic CRH neurons in stressed animals expressed PCREB. Following systemic administration of dexamethasone (100 micrograms/day) for 2.5 days, PCREB immunostaining was completely abolished in parvocellular CRH-producing neurons after ether or handling stress. Dexamethasone had no apparent effect on CREB immunostaining. These results demonstrate that glucocorticoids suppress CREB phosphorylation in hypophysiotropic CRH neurons and suggest that prevention of CREB phosphorylation is a possible mechanism for feedback inhibition of CRH biosynthesis by glucocorticoids.

Intravascular tumor: a previously unreported finding of glucagonoma.

Glucagonoma is a relatively rare pancreatic islet cell tumor. Historically, these tumors present a typical constellation of symptoms including diabetes, weight loss, anemia, necrolytic migratory erythematous rash, and propensity for thrombosis. This clinical presentation is described as the glucagonoma syndrome. The syndrome can be confirmed with the use of serum measurements of glucagon levels and immunohistochemical assay of the tumor. Variations from the classic syndrome have been described, and serum measurements of glucagon in patients with suspected islet cell tumors can identify subsets of patients with glucagonoma who do not exhibit the classic syndrome. In our case, the unusual presentation of glucagonoma included the previously unreported component of an intravascular venous extension of tumor.

Estrogen inhibits hypothalamic pro-opiomelanocortin gene expression in hypothalamic neuronal cultures.

Many in vitro studies show estrogen regulation of the hypothalamic pro-opiomelanocortin (POMC) system, including a decrease in hypothalamic POMC mRNA after estradiol treatment. Because such in vivo experiments do not allow one to determine whether peripheral, interacting systems or extra-hypothalamic brain regions are involved in this regulation, we sought to establish whether estrogen acts directly in hypothalamus to decrease POMC mRNA. Using an in vitro approach, we studied effects of estradiol (E2) on POMC/cyclophilin mRNA concentrations (RNAse protection assays) in neuronal cultures derived from day 17 fetal rat hypothalamus. Chemically defined medium was deprived of progesterone for 2 days prior to E2 treatment and for the duration of the study. E2 (10(-13)-10(-9) M) dose-dependently decreased POMC mRNA concentrations during a 2-day treatment. Whereas the lowest dose (10(-13) M) of E2 resulted in a statistically significant 44% decrease in POMC mRNA concentrations relative to control cultures, this inhibitory effect was lost because higher doses (10(-11) and 10(-9) M) did not produce statistically significant decrements (22 and 16%, respectively) in POMC mRNA concentrations. Additional time course studies revealed that this decrease in POMC mRNA can be seen as early as 4 h after E2 (10(-13) M) treatment. We conclude that E2 inhibition of POMC mRNA concentrations in hypothalamic neuronal cultures indicates that this inhibition can occur directly in hypothalamus.

Subdiaphragmatic vagotomy inhibits intra-abdominal interleukin-1 beta stimulation of adrenocorticotropin secretion.

Although interleukin (IL)-1 beta activates the hypothalamic-pituitary-adrenal (HPA) axis, the mechanisms by which peripheral IL-1 beta acutely stimulates adrenocorticotropin (ACTH) secretion are not clear. Recently, the vagus has been implicated in mediating peripheral cytokine signalling of the brain. To investigate a possible central mechanism for peripheral cytokine stimulation of the HPA axis, we tested the hypothesis that the vagus mediates IL-1 beta activation of the HPA axis by an intra-abdominal stimulus. We studied the effect of subdiaphragmatic vagotomy on plasma ACTH stimulation in rats by intraperitoneal (i.p.) IL-1 beta. Adult male Sprague-Dawley rats underwent subdiaphragmatic vagotomy or sham surgery 1 week prior to study. Rats were killed 1 and 2 h after i.p. saline (control) and low- (4 micrograms/kg) and high-dose (20 micrograms/kg) IL-1 beta. Vagotomy markedly attenuated plasma ACTH secretion at 2 h after high-dose IL-1 beta stimulation and abolished plasma ACTH secretion at 2 h after low-dose IL-1 beta stimulation. At 1 h after low-dose IL-1 beta, stimulation of plasma ACTH in vagotomized animals was also markedly diminished compared to sham animals. However, vagotomy did not alter stimulation of plasma corticosterone at 1 or 2 h after low-dose IL-1 beta or at 2 h after high-dose IL-1 beta. In addition, vagotomy did not alter stimulation of plasma ACTH or corticosterone secretion by insulin-induced hypoglycemia. We conclude that: (1) the vagus plays an important role in stimulation of ACTH secretion by intra-abdominal (i.p.) IL-1 beta; (2) stimulation of corticosterone secretion by i.p. IL-1 beta is not altered by vagotomy; and (3) the inhibitory effect of vagotomy on activation of the HPA axis appears to be specific for immune stimulation by cytokines.

The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress.

We have shown that ADX and HYPOX rats exhibit a markedly increased sensitivity to the lethal effects of IL-1-beta and LPS compared to sham controls with an intact HPAA. These results indicated that the reports of lethal effects of cytokines and LPS which generates cytokines in mice with a compromised HPAA were not idiosyncratic or specific to mice but represented a general response that would have been expected in any organism with a compromised HPAA. We further demonstrated that protection against lethal effects due to IL-1-beta or LPS could be produced by treating ADX rats with glucocorticoid in a quantity estimated to be equivalent to corticosterone secretion provoked during stress. In contrast, we found that acutely stalk-sectioned rats with pituitaries disconnected from hypothalamic regulation did not show a markedly increased susceptibility to lethal effects of LPS as did ADX or HYPOX rats. Although a minority of stalk-sectioned rats were killed by LPS, the majority of rats were protected from lethal actions of LPS. This response suggested that an intact pituitary-adrenal axis without the normal hypothalamic control could still provide significant protection presumably due to generation of cytokines which stimulated the pituitary over several hours. The results from our lethality studies clearly underscore the importance of activating the stress axis and increasing glucocorticoid secretion to protect against potentially lethal effects of cytokines that can be induced by immune, infectious, or inflammatory stimuli. Cytokine-stimulated effects can initially result in beneficial actions to the host by promoting immune/inflammatory responses that are protective in nature and help defend against a variety of invading stimuli (infectious, immune, inflammatory, traumatic, neoplastic). Normally the HPAA responds to cytokine stimulation by ultimately increasing glucocorticoid secretion in order to counterregulate cytokine actions, modulate the host response, and protect the host from excessively catabolic effects of unregulated cytokine generation and actions. For many years, clinicians have recognized that patients with deficient glucocorticoid secretion (e.g., Addison's disease or pituitary ACTH deficiency) require increased glucocorticoid replacement during episodes of fever, infection, or inflammatory stress. However, the reasons why stress-equivalent glucocorticoid replacement were required were not entirely clear. Now, we understand that glucocorticoids are critically important for protecting the host against its own defense mechanisms so that the stimulation of cytokines can facilitate a protective response against an invading insult without also killing the host.

Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Following presentation and diagnosis, microprolactinomas usually follow a benign course and rarely progress to macroprolactinomas. However, clinically significant enlargement of prolactinomas during pregnancy, presumably related to estrogen stimulation, has been reported. This report describes a patient with amenorrhea and hyperprolactinemia and a microadenoma by computed tomography scan who developed a macroprolactinoma within 10 months after being placed on estrogen therapy. We propose that exogenous estrogen administration in this patient most likely promoted growth from a microprolactinoma to a macroprolactinoma. This case emphasizes the primary role of dopaminergic agonist therapy in the management of pathological hyperprolactinemia and suggests that estrogen therapy should not be casually given to patients with known prolactinomas to avoid the possibility of promoting tumor growth. A correlate of this approach is that caution regarding estrogen therapy should also be exercised in patients with idiopathic hyperprolactinemia who might have an occult microprolactinoma which could grow following estrogen stimulation. If estrogen treatment is deemed necessary, dopaminergic agonist therapy should also be used prophylactically to prevent potential tumor growth due to estrogen. The patient should then be carefully monitored with periodic serum PRLs and for the development of clinical manifestations suggesting pituitary growth. An imaging study should be performed when there is a significant increase in serum PRL or the development of new clinical manifestations.

Modulation of corticotropin-releasing hormone stimulated cyclic adenosine monophosphate production by brain cells.

Corticotropin-releasing hormone (CRH) is believed to have a role as an important brain neuroregulator acting through specific receptors coupled to adenylate cyclase in addition to its major role in regulating pituitary adrenocorticotropin synthesis and secretion. To study the potential modulatory effects of various regulators and the central effects of CRH, we studied the effects of phorbol ester myristate acetate (PMA), arginine vasopressin (AVP), corticosterone, dexamethasone, and progesterone on CRH stimulation of cyclic adenosine monophosphate (cAMP) production in extrahypothalamic forebrain cell cultures derived from day 17 gestation fetal rats. These cultures contain CRH receptors with similar characteristics as those in anterior pituitary and brain. CRH (10(-9) - 10(-7) M) stimulated cAMP in a dose-dependent fashion and maximal stimulation was clearly seen at 10(-7) M CRH. Incubation of the cells with PMA (10(-7) M), a protein kinase C (PKC) agonist, had no effect on basal cAMP, but potentiated CRH-stimulated cAMP. AVP (10(-8), 10(-7) M) had no effect on basal nor CRH-stimulated cAMP accumulation. Corticosterone (10(-7), 10(-6) M) or dexamethasone (10(-9) - 10(-7) M) pre-incubation for 18 h did not diminish basal cAMP levels nor inhibit CRH-induced stimulation of cAMP. However, corticosterone inhibited CRH-induced cAMP production in anterior pituitary cells. Neither did exposure to progesterone (2 x 10(-8) M) modulate basal cAMP, CRH-induced cAMP production nor the potentiation of CRH stimulation by PMA. The data demonstrate that CRH receptors in dissociated fetal extrahypothalamic forebrain cell cultures are coupled to an adenylyl cyclase/cAMP second messenger system similarly as shown in studies with anterior pituitary membranes.(ABSTRACT TRUNCATED AT 250 WORDS)

Protein kinase C activators stimulate beta-endorphin secretion from hypothalamic cells.

Relatively little is known about the regulation of secretion of hypothalamic beta-endorphin, the potent opioid that is believed to play a variety of physiological roles in brain. Previous work has shown that arginine vasopressin (AVP), which acts in brain primarily via activation of the phosphoinositol (PI) second messenger system, stimulates secretion of hypothalamic beta-endorphin. To test the hypothesis that activators of protein kinase C (PKC), which is activated following PI hydrolysis, stimulates secretion of beta-endorphins from hypothalamus, we studied the separate effects of stimulators of PKC including phorbol ester 12-myristate-13-acetate (PMA) and 1-oleolyl-2-acetyl glycerol (OAG- a diacyl glycerol analogue) on secretion of immunoreactive (IR-) beta-endorphin (measured by RIA) from dissociated fetal rat hypothalamic cell cultures. We also studied AVP and angiotensin II (Ang II), hypothalamic peptides which activate the PI second messenger pathway, and interactions of PMA and forskolin (FSK), an activator of the cyclic AMP/protein kinase A (PKA) pathway. PMA, OAG, AVP, and Ang II stimulated IR-beta-endorphin secretion. The stimulatory effect of both PMA and FSK on IR-beta-endorphin secretion was greater than that of PMA or FSK alone and was essentially additive.(ABSTRACT TRUNCATED AT 250 WORDS)

In vitro regulation of immunoreactive beta-endorphin secretion from adult and fetal hypothalamus by sequential stimulation with corticotropin-releasing hormone.

Previous work has shown corticotropin-releasing hormone (CRH) stimulation of beta-endorphin (END) secretion from hypothalamus. We tested the hypothesis that CRH stimulation of beta-END (measured by radioimmunoassay) from hypothalamic explants is dependent on: (1) ovine CRH dose, (2) pattern and sequence of CRH stimulation, (3) androgen status, and (4) hypothalamic age. Hypothalami from adult male rats and day 17 fetal rats were studied. In adult hypothalami, CRH-stimulated immunoreactive (IR)-beta-END secretion with 10(-7) M was greater than that with 10(-8) M CRH and showed dose-dependent stimulation. Serial stimulation for 20 min by 10(-8) M CRH followed by a 40 min interval without CRH stimulation resulted in a brief stimulation of secretion of IR-beta-END and also secretion of IR-alpha-melanocyte-stimulating hormone (MSH), another peptide derived from pro-opiomelanocortin, the precursor of beta-END. Subsequent stimulation with 10(-6) M CRH showed a desensitization to stimulation despite readily releasable pools of IR-beta-END shown by potassium-induced depolarization. In addition, prolonged stimulation for 1 h with 10(-7) M CRH or increasing concentrations of CRH produced a sustained increase in IR-beta-END release as long as CRH was present. Dihydrotestosterone treatment had no effect on basal nor CRH-stimulated IR-beta-END release in orchiectomized rats. The pattern of IR-beta-END secretion from fetal hypothalamic explants exposed briefly (20 min) or for a prolonged period (1 h) to CRH was similar to that from adult explants. These results demonstrate that: (1) CRH-stimulated IR-beta-END secretion from hypothalamus is dose-dependent.(ABSTRACT TRUNCATED AT 250 WORDS)

Brain corticotropin-releasing hormone receptors on neurons and astrocytes.

UNLABELLED: Corticotropin-releasing hormone (CRH) exerts many potent effects within brain and is considered an important brain neuroregulator. CRH acts via receptors that are widely distributed throughout brain which exhibits highest CRH receptor concentrations in extrahypothalamic regions. We have previously characterized CRH receptors in heterogeneous extrahypothalamic forebrain cell cultures consisting of neurons and glia, and have shown them to exhibit similar kinetic and pharmacological characteristics as CRH receptors in pituitary and in situ brain. However, it is not known whether CRH receptors are present on neurons, glia or both. We tested the hypothesis that CRH receptors are present on neurons in extrahypothalamic forebrain cell cultures derived from day 17-18 fetal rats by characterizing receptors in predominantly neuronal (N), glial/astrocytic (G) cultures and mixed (M) cultures. Mean CRH receptor concentrations (fmol/mg protein) in N (10.4), G (9.4), and M (9.8) cultures were similar. Following Scatchard analyses derived from competition curves, all cell populations exhibited similar mean high-affinity/low-capacity (Kd = 1.0-1.9 nM; Bmax = 183-388 fmol/mg protein) and low-affinity/high-capacity (Kd = 92-104 nM; Bmax = 2034-5008 fmol/mg protein) classes of binding sites. IN CONCLUSION: (1) Neurons and astrocytes in fetal extrahypothalamic brain cell cultures contain CRH receptors which exhibit similar concentrations and similar kinetic characteristics. (2) These observations suggest that biological effects of CRH in brain could be mediated via actions on neurons and/or glial astrocytes.

Activation of cyclic AMP second messenger system stimulates secretion of beta-endorphin from fetal hypothalamic cells.

Relatively little is known about physiological regulators of hypothalamic beta-endorphin (END) secretion and mechanisms by which they stimulate secretion. We sought to determine whether activation of the cyclic AMP (cAMP) second messenger pathway was involved in stimulating hypothalamic beta-END secretion from dissociated fetal hypothalamic cells in culture. Forskolin (FSK), a direct activator of adenylate cyclase which stimulates cAMP formation, stimulated immunoreactive (IR)-beta-END secretion. Because FSK can also stimulate independent of increased cAMP formation, we studied dibutyryl cAMP and 8-bromo-cAMP, analogues of cAMP, which also stimulated IR-beta-END secretion. From these studies we conclude: (1) activation of the cAMP second messenger system stimulates IR-beta-END secretion from hypothalamic cells and supports the rationale that endogenous regulators which stimulate this pathway could be involved in the physiological regulation of hypothalamic beta-END secretion; (2) coupling between the cAMP second messenger pathway and stimulation of hypothalamic beta-END secretion which is presumably present at maturity (adulthood) originates at early stages of development (fetal life).

Corticotropin-releasing hormone and dexamethasone do not alter secretion of immunoreactive beta-endorphin from dissociated fetal hypothalamic cell cultures.

Corticotropin-releasing hormone (CRH) and glucocorticoids are major regulators of the hypothalamic-pituitary-adrenal (HPA) axis controlling secretion of beta-endorphin and other pro-opiomelanocortin (POMC)-derived peptides from pituitary. Although previous work has shown that CRH stimulates secretion of beta-endorphin from adult hypothalamic explants, and that glucocorticoids can inhibit basal and stimulated secretion of POMC-derived peptides from pituitary, the role of glucocorticoids on hypothalamic beta-endorphin secretion is not known. Studies were performed to assess the effects of CRH and dexamethasone, a potent glucocorticoid, on secretion of immunoreactive (IR) beta-endorphin from dissociated fetal hypothalamic cell cultures. CRH (10(-9)-10(-6) M) did not stimulate secretion of IR-beta-endorphin from hypothalamic cells which did release IR-beta-endorphin upon potassium-induced depolarization. However, CRH did stimulate IR-beta-endorphin secretion from fetal hypothalamic explants which were similar to hypothalamic tissue from which dissociated hypothalamic cell cultures were derived. Exposure of cells to dexamethasone (10(-6) M) did not inhibit basal or potassium-stimulated release of IR-beta-endorphin. These results indicate that: (1) dissociated fetal hypothalamic cells in culture do not exhibit a functional CRH receptor coupled to stimulation of IR-beta-endorphin secretion; (2) exposure of hypothalamic cells to dexamethasone does not inhibit basal nor depolarization-induced release of IR-beta-endorphin; and (3) dissociated fetal hypothalamic cells may have limited utility in elucidating specific regulatory relationships because of in vitro conditions and/or cytoarchitectural relationships.

Thoracic stimulation and prolactin secretion.

Although galactorrhea and/or enhanced prolactin (PRL) secretion have been reported with a variety of thoracic stimuli, the effect of thoracic stimulation on dynamic prolactin secretion is not clear. A 49-year-old woman with ventilatory muscle weakness from polio presented with galactorrhea, and intermittent hyperprolactinemia but regular menses. The galactorrhea was noted following the use of a new, tight fitting cuirass (thoracic apparatus which assists ventilation). To determine if the new, "tight" cuirass elicited enhanced PRL secretion, and to assess more extensively the effect of such thoracic stimulation on PRL secretion, serum PRL was measured during brief and prolonged stimulation, sleep, and pharmacological manipulation of PRL. Basal PRL was normal (less than 25 ng/ml) and increased during brief stimulation (1 hour) with the "tight" (137%) and "loose" cuirass (140%). Although the absolute increments were similar, the "tight" cuirass elicited an earlier PRL peak than the "loose" cuirass and the PRL began to decrease while the "tight" cuirass was still functioning. Several hours of thoracic stimulation resulted in a transient rise in PRL and a fall to normal, prestimulatory levels despite persistent stimulation. During this stimulation, PRL did not rise after sleep nor after insulin-induced hypoglycemia despite normal cortisol and GH increments, but the PRL response after TRH was exaggerated.(ABSTRACT TRUNCATED AT 250 WORDS)

Production of immunoreactive adrenocorticotropin and beta-endorphin by hypothalamic and extrahypothalamic brain cells.

UNLABELLED: Despite many in vivo studies, little is known about brain regulation of POMC synthesis or regulation of secretion of POMC-related peptides. To test the hypothesis that dissociated brain cells in culture can produce and release POMC-related peptides, immunoreactive (IR)-adrenocorticotropin (ACTH) and beta-endorphin were measured in cells and media of dissociated cell cultures incubated up to 38 days. Fetal rat hypothalamic and extrahypothalamic forebrain cells were maintained in serum free medium. IR-ACTH and beta-endorphin were measured by radioimmunoassay in concentrated cells and media after various incubation times using two ACTH (mid-portion = R4; carboxy-portion directed = KEND) antisera and a beta-endorphin antiserum. IR-ACTH and IR-beta-endorphin in hypothalamic and extrahypothalamic cells and in media (cumulative) were greater than quantities in cells before culture. Peak hypothalamic cellular content of IR-ACTH (5.3 fmol/10(6) cells-R4; 4.7 fmol/10(6) cells-KEND) and content of IR-beta-endorphin (32.0 fmol/10(6) cells) occurred on days 16, 9 and 23, respectively. Peak extrahypothalamic content of IR-ACTH (2.9 fmol/10(6) cells-R4; 1.0 fmol/10(6) cells-KEND) and content of IR-beta-endorphin (10.8 fmol/10(6) cells) was also seen on different days, was lower than hypothalamic content and was not always concurrent with peak hypothalamic content. Gel filtration chromatography revealed that the predominant forms of IR-ACTH and IR-beta-endorphin in hypothalamic cell extracts co-eluted with synthetic ACTH1-39 and beta-endorphin. Changes in molar ratios of IR-ACTH and IR-beta-endorphin also suggested a differential regulation of different POMC derivatives. CONCLUSIONS: (1) IR-ACTH and IR-beta-endorphin are produced by hypothalamic and extrahypothalamic forebrain cells in culture: and (2) dissociated brain cell cultures can be used as a potential model for studying regulation of POMC-related peptides in brain.

Pituitary hyposecretion and hypersecretion produced by a Rathke's cleft cyst presenting as a noncystic hypothalamic mass.

A 53-year-old man presented with polydipsia, polyuria, lightheadedness on standing, and syncope. Visual field deficits suggesting left optic tract compression and pituitary dysfunction consisting of diabetes insipidus, hyperprolactinemia, and anterior pituitary insufficiency were diagnosed. On the computed tomography scan, an isodense, ring-enhancing, parasellar mass was localized primarily in the suprasellar region and also extended into the sella. It was believed that the pituitary hormone hypersecretion and hyposecretion were due to hypothalamic dysfunction from the mass which was initially believed to be a craniopharyngioma. At surgery a Rathke's cleft cyst was resected. The unusual presentation of this Rathke's cleft cyst presenting as a hypothalamic lesion is discussed.

Differential effects of adrenocorticotropin(1-24) on [3H]2-deoxy-D-glucose uptake in cultured cells derived from different brain regions.

The effect of adrenocorticotropin(1-24) (ACTH(1-24)) on the uptake of [3H]2-deoxy-D-glucose ([3H]2-DG) was compared in cell cultures derived from two regions (hypothalamus, and extrahypothalamic forebrain) of fetal rat brain. Under control conditions, [3H]2-DG uptake was similar in extrahypothalamic (10.9 +/- 1.1 nmol/mg protein/5 min) and hypothalamic (11.9 +/- 1.3) cells. No significant effect of ACTH (1-24) (10(-7) to 10(-5) M) was found on uptake of [3H]2-DG in extrahypothalamic cells. In contrast, in hypothalamic cells, a potent stimulatory effect (P less than 0.0001) up to 174% over the control value of [3H]2-DG uptake was produced by these concentrations of ACTH(1-24). This study suggests that ACTH may be a stimulator of brain glucose uptake, and that this effect varies in different brain regions.

Characterization of corticotropin-releasing factor receptors in dissociated brain cell cultures.

UNLABELLED: Although corticotropin-releasing factor (CRF) receptors have been identified throughout the brain, relatively little is known about the regulation of CRF receptors. Recent investigations aimed at developing an in vitro model for studying the regulation of CRF receptors demonstrated CRF binding in brain cell cultures. To test the hypothesis that dissociated brain cell cultures contain CRF receptors and may provide a model for studying their regulation, studies characterizing binding of labeled CRF were performed. Dissociated cells derived from hypothalamus and extrahypothalamic forebrain (predominantly cortex) of day 17 fetal rats were maintained in chemically defined medium. We used a stable 125I-labeled analog of ovine CRF, 125I-Tyro-ovine CRF (125I-oCRF), to identify and characterize CRF receptors. Although specific binding of 125I-oCRF was demonstrated in both hypothalamic and extrahypothalamic cell cultures, the concentration of CRF receptors was much greater (3-5 fold) in extrahypothalamic cells. Binding of 125I-oCRF in extrahypothalamic cells was saturable and was composed of high affinity (Kd = 0.51 nM) and low affinity (Kd = 17.25 nM) sites. Pharmacological displacement of labeled CRF from cells with a variety of CRF fragments and analogs was similar to that in studies of pituitary and brain homogenates. Extrahypothalamic cells studied at several times between 4 and 13 days in culture revealed an increase in the number of CRF receptors; the concentration of CRF receptors at 13 days was 3.5 times that observed at 4 days. Studies directed toward determining whether CRF receptor concentration could be modulated by CRF, adrenocorticotropic hormone, atropine or a CRF antagonist showed a change (36% decrease) only in response to chronic exposure with CRF. CONCLUSIONS: (1) dissociated fetal rat brain cell cultures derived from extrahypothalamic forebrain and hypothalamus contain CRF receptors; (2) CRF receptors in brain cells exhibit a differential distribution and characteristics similar to those previously reported in brain and pituitary; (3) dissociated fetal rat brain cell cultures may provide a relatively simplified in vitro model for studying the regulation of CRF receptors; and (4) CRF down-regulates its own receptor in extrahypothalamic forebrain cells.

Effect of enzyme inhibitors on profiles of IR-ACTH/beta-endorphin in brain and pituitary.

Processing of pro-opiomelanocortin (POMC) in brain and pituitary results in various proportions of multiple peptides appearing as immunoreactive (IR-) ACTH and IR-beta-endorphin. Because it is desirable that molecular profiles of POMC-related peptides reflect in vivo processing and not isolation artifact, inhibition of proteolytic activity during extraction is critical. Although enzyme inhibitors are frequently used during extraction of POMC-related peptides, their benefit or necessity has not been established. To determine the benefit of using enzyme inhibitors for studying molecular profiles of IR-ACTH and IR-beta-endorphin from rat brain and pituitary, chromatographic profiles were compared to assess the effect of each of several enzyme inhibitors. Results suggested that the enzyme inhibitors studied provided no additional benefit in terms of inhibition of extraction proteolysis over that provided by a strong acid and heat inactivation.